<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056194</url>
  </required_header>
  <id_info>
    <org_study_id>XW10172-104</org_study_id>
    <nct_id>NCT05056194</nct_id>
  </id_info>
  <brief_title>Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XWPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XWPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following screening visit and verification of inclusion/exclusion criteria and informed&#xD;
      consent, participants will undergo a multiple sleep latency test (MSLT) and polysomnogram&#xD;
      (PSG) assessments to confirm eligibility for randomization. Participants will be randomized&#xD;
      to two groups: placebo or XW10172 MR. The drug will be taken orally at bedtime for 6 weeks of&#xD;
      treatment that will consist of a 2-week dose escalation/titration period and a 4-week&#xD;
      stable-dose maintenance period. There will be a 2-week safety period following dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between XW10172 MR and placebo in the change from baseline to end-of-maintenance in the Epworth Sleepiness Scale.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between XW10172 and placebo in the change from baseline to end-of-maintenance in the Caregiver Global Impression of Change.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between XW10172 MR and placebo in the change from baseline to end-of-maintenance in the Multiple Sleep Latency Test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between XW10172 MR and placebo in the change from baseline to end-of-maintenance in the Parkinson's Fatigue Scale 16.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between XW10172 MR and placebo in the change from baseline to end-of-maintenance in the Brief Assessment of Cognition composite score</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Excessive Daytime Somnolence</condition>
  <arm_group>
    <arm_group_label>Valiloxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XW10172 Modified Release (MR) Granules for Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Granules for Oral Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valiloxybate</intervention_name>
    <description>XW10172 MR Granules for Oral Suspension</description>
    <arm_group_label>Valiloxybate</arm_group_label>
    <other_name>XW10172 MR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Granules for Oral Suspension</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Parkinson's disease consistent with the UK-PD Society Brain Bank Criteria&#xD;
             and PD duration at least 1 year with modified Hoehn and Yahr stage 1-3 in the OFF&#xD;
             state.&#xD;
&#xD;
          -  Patient reported history of excessive daytime sleepiness (e.g., frequent dozing,&#xD;
             nodding, or naps).&#xD;
&#xD;
          -  Anti-Parkinson's medications at stable doses for at least 1 month prior to the&#xD;
             Baseline Visit and can maintain a fixed, stable dose throughout the study&#xD;
&#xD;
          -  Epworth Sleepiness Scale score of &gt;10 at screening.&#xD;
&#xD;
          -  Female participants of childbearing potential must test negative in a serum pregnancy&#xD;
             test at Screening and have a negative urine pregnancy test at the Baseline and Visit.&#xD;
             Women with childbearing potential must use an acceptable method of contraception&#xD;
             during the study and for at least 30 days after completion of dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atypical or secondary parkinsonism&#xD;
&#xD;
          -  Significant medical conditions.&#xD;
&#xD;
          -  Evidence of moderate or severe sleep disordered breathing.&#xD;
&#xD;
          -  Drugs that affect sleep including CNS depressants and stimulants.&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) examine score &lt;24.&#xD;
&#xD;
          -  Hospital Anxiety and Depression Scales (HADS) &gt;11.&#xD;
&#xD;
          -  Have an occupation that requires variable shift work or routine night shifts or travel&#xD;
             across two or more-time zones.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Canafax, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>XWPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Zib</last_name>
    <phone>650-885-9682</phone>
    <email>Beth.Zib@XWPharma.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

